Evidence map›Paper›PMID 39338474›Full record

ArticleMicroorganisms2024

Analysis of Cultured Gut Microbiota Using MALDI-TOF MS in COVID-19 Patients from Serbia during the Predominance of the SARS-CoV-2 Omicron Variant.

Aleksandra Patić, Gordana Kovačević, Vladimir Vuković, Ivana Hrnjaković Cvjetković, Mioljub Ristić, Biljana Milosavljević, Deana Medić, Milan Djilas, Jelena Radovanov, Aleksandra Kovačević and 3 more

Abstract read
In one paragraph

Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aleksandra PatićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.ORCID 0000-0002-7068-2882
Gordana KovačevićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Vladimir VukovićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.ORCID 0000-0002-9561-7825
Ivana Hrnjaković CvjetkovićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Mioljub RistićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.ORCID 0000-0002-6923-189X
Biljana MilosavljevićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Deana MedićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Milan DjilasInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Jelena RadovanovInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Aleksandra KovačevićClinic of Nephrology and Clinical Immunology, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia.
Tatjana PustahijaInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Dragana BalaćInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
Vladimir PetrovićInstitute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The currently dominant SARS-CoV-2 omicron variant, while causing mild respiratory symptoms, exhibits high transmissibility, drug resistance, and immune evasion. We investigated whether the presence of the SARS-CoV-2 affected the dynamics of fecal microbial composition isolated in culture in moderate COVID-19 patients. Blood, stool, and medical records were collected from 50 patients with confirmed SARS-CoV-2 infection. Two samples were taken per patient, at disease onset (within 5 days) and after symptom resolution (30-35 days). The part of the gut microbiota identifiable using MALDI-TOF MS was analyzed, and inflammatory cytokines and blood markers were measured in serum. The analysis identified 566 isolates at the species level, including 83 bacterial and 9 fungal species. Our findings indicate a change in the gut microbiota composition isolated in culture during the initial phase of infection, characterized by the proliferation of opportunistic bacteria such as

Indexed as

COVID-19gut microbiotaMALDI-TOF MSSARS-CoV-2

Identifiers

PMID39338474
PMCPMC11433956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.